| Literature DB >> 31114329 |
Yuliuming Wang1, Hanqing Hu1, Meng Wang1, Xiao Han1, Qian Zhang1, Lei Yu1, Yinggang Chen1, Guiyu Wang1.
Abstract
Purpose: Acute obstructive colorectal cancer is a common emergency that requires decompression immediately. The aim of the study was to compare short-term and long-term results of acute obstructive colorectal cancer treated by the self-expanding metallic stent (SEMS) as a bridge to surgery (BTS) versus emergency surgery. Patients and methods: We retrospectively reviewed 78 patients who were diagnosed as acute obstructive colorectal cancer that underwent elective surgery after stent insertion (stent group, N=37) or emergency surgery (emergency group, N=41) from January 2013 to October 2016. The Kaplan-Meier method was conducted to calculate overall survival. Univariate analyses were performed using the Mann-Whitney U analysis, Pearson's chi-square test, and Fisher's exact test. In addition, continuous variables were compared using the Student's t-test.Entities:
Keywords: bridge to surgery; obstructive colorectal cancer; self-expanding metallic stent
Year: 2019 PMID: 31114329 PMCID: PMC6497858 DOI: 10.2147/CMAR.S192801
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
Figure 1Patient selection flowchart. A total of 78 patients diagnosed with acute obstructive colorectal cancer who underwent elective surgery after stent insertion or emergency surgery from January 2013 to October 2016 were included in this study.
Abbreviation: SEMS, self-expanding metallic stent.
The obstruction site of SG and EG
| Obstruction site | SG (n=37) | EG (n=41) | |
|---|---|---|---|
| Cecum | 3 | 3 | 0.871 |
| Ascending colon | 5 | 7 | |
| Hepatic flexure | 2 | 4 | |
| Transverse colon | 4 | 3 | |
| Splenic flexure | 4 | 4 | |
| Descending colon | 6 | 3 | |
| Sigmoid colon | 13 | 17 |
Abbreviations: SG, stent group; EG, emergency group.
Baseline characteristics of patients in SG and EG
| Characteristics | SG (N=37) | EG (N=41) | ||
|---|---|---|---|---|
| Gender, n (%) | Male | 21 (56.8) | 25 (61.0) | 0.441 |
| Female | 16 (43.2) | 16 (39.0) | ||
| Age group, n (%) | 40–59 | 13 (35.1) | 11 (26.8) | 0.695 |
| 60–79 | 20 (54.1) | 24 (58.5) | ||
| ≥80 | 4 (10.8) | 6 (14.6) | ||
| Age (years,range)a | 66.1±10.3 | 65.4±11.7 | 0.790 | |
| CEA before surgery, n (%) | <5 ng/mL | 16 (43.2) | 19 (46.3) | 0.482 |
| ≥5 ng/mL | 21 (56.8) | 22 (53.7) | ||
| Tumor location, n (%) | Right-sided colon | 11 (29.7) | 15 (36.6) | 0.345 |
| Left-sided colon | 26 (70.3) | 26 (63.4) | ||
| Underlying disease, n (%) | 16 (43.2) | 19 (46.3) | 0.482 | |
| T stage, n (%) | pT2 | 6 (16.2) | 5 (12.2) | 0.877 |
| pT3 | 26 (70.3) | 30 (73.2) | ||
| pT4 | 5 (13.5) | 6 (14.6) | ||
| N stage, n (%) | pN0 | 16 (43.2) | 19 (46.3) | 0.768 |
| pN1 | 13 (35.1) | 16 (39.0) | ||
| pN2 | 8 (21.7) | 6 (14.6) | ||
| M stage, n (%) | pM0 | 30 (81.1) | 36 (87.8) | 0.306 |
| pM1 | 7 (18.9) | 5 (12.2) | ||
| AJCC TNM stage , n (%) | II | 14 (37.9) | 17 (41.5) | 0.713 |
| III | 16 (43.2) | 19 (46.3) | ||
| IV | 7 (18.9) | 5 (12.2) | ||
| Histological grade, n(%) | Well-differentiated | 7 (18.9) | 11 (26.8) | 0.710 |
| Moderately-differentiated | 23 (62.2) | 23 (56.1) | ||
| Poorly-differentiated | 7 (18.9) | 7 (17.1) | ||
| Histological type, n (%) | Adenocarcinoma | 33 (89.2) | 37 (90.2) | 0.548 |
| Mucous/signet-ring cell | 4 (10.8) | 4 (9.8) | ||
Note: aMean ± SD.
Abbreviations: AJCC, American Joint Committee on Cancer; SG, stent group; EG, emergency group.
Figure 2Analysis of preoperative serum albumin level of patients in SG and EG. The median of serum albumin level was 36.6 and 34.1 for the stent group and emergency group, respectively. * Statistically significant (P<0.05).
Abbreviations: SG, stent group; EG, emergency group.
Preoperative condition of patients in SG and EG
| SG (N=37) | EG (N=41) | |||
|---|---|---|---|---|
| Serum albumin level (g/L, range)a | 36.6 | 34.1 | 0.020 | |
| ASA risk score, n (%) | I/II | 27 (73.0) | 20 (48.8) | 0.025 |
| III/IV | 10 (27.0) | 21 (51.2) | ||
Note: aMedian.
Abbreviations: SG, stent group; EG, emergency group; ASA, American Society of Anesthesiologists physical status classification system.
Postoperative outcomes of patients in SG and EG
| SG (N=37) | EG (N=41) | |||
|---|---|---|---|---|
| Operation time (min,range)a | 115 (90–240) | 180 (90–255) | <0.001 | |
| Blood loss (mL,range)a | 200 (50–350) | 200 (50–650) | 0.183 | |
| Exhaust time (day, range)a | 3 (1–5) | 3 (1–6) | 0.105 | |
| Diet time (day, range)a | 4 (2–6) | 5 (3–10) | 0.015 | |
| Postoperative hospital stay | 11 (6–31) | 12 (6–40) | 0.105 | |
| Harvested lymph nodes (range)a | 14 (4–36) | 11 (4–26) | 0.003 | |
| Harvested lymph nodes, n (%) | <12 | 8 (21.6) | 20 (48.8) | 0.011 |
| ≥12 | 29 (78.4) | 21 (51.2) | ||
| Surgery technique, n (%) | Open | 32 (86.5) | 41 (100) | 0.021 |
| Laparoscopic | 5 (13.5) | 0 | ||
| Stoma, n (%) | Temporary | 3 (8.1) | 6 (14.6) | 0.295 |
| Permanent | 5 (13.5) | 14 (34.1) | 0.030 | |
| Total stoma creation, n (%) | 8 (21.6) | 20 (48.8) | 0.011 | |
| Postoperative complication, n (%) | 6 (16.2) | 11 (26.8) | 0.196 | |
| Anastomotic leak, n (%) | 3 (8.1) | 2 (4.9) | 0.451 | |
| Postoperative ileus, n (%) | 2 (5.4) | 3 (7.3) | 0.549 | |
| Atelectasis, n (%) | 0 | 1 (2.4) | 0.526 | |
| Wound abscess, n (%) | 1 (2.7) | 2 (5.1) | 0.539 | |
| Intra-abdominal abscess, n (%) | 0 | 3 (7.3) | 0.140 | |
| Mortality, n (%) | 0 | 2 (4.9) | 0.273 | |
Note: aMedian.
Abbreviations: SG, stent group; EG, emergency group.
Figure 3Overall survival of patients in SG and EG. The median overall survival was 36 months for both groups.
Abbreviations: SG, stent group; EG, emergency group.
EORCT QLQ-C30 results of survival patients in SG and EG
| SG (n=23) | EG (n=21) | ||
|---|---|---|---|
| GQL a | 66.67 | 50.00 | 0.026 |
| Physical function a | 73.33 | 53.33 | 0.048 |
| Role function a | 50.00 | 33.33 | 0.023 |
| Emotional function a | 91.67 | 83.33 | 0.031 |
| Cognitive function a | 100.00 | 83.33 | 0.038 |
| Social function a | 50.00 | 33.33 | 0.025 |
Note: aMedian.
Abbreviations: SG, stent group; EG, emergency group; GQL, global quality of life; EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30, Quality of Life Questionnaire-Core 30.